Drug Profile
Research programme: neuroinflammation targeting agents - ShangPharma Innovation/SRI International
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator ShangPharma; SRI International
- Class
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Alzheimer's-disease in China
- 28 Nov 2021 No recent reports of development identified for research development in Neurodegenerative-disorders in China
- 09 Oct 2017 Research programme: neuroinflammation targeting agents - ShangPharma Innovation/SRI International is available for licensing as of 09 Oct 2017.